BDM-I

BDM-I is an experimental small-molecule antimicrobial agent described in the early 2000s as a broad-spectrum inhibitor of diverse pathogens, including certain bacteria, fungi, and protozoa. It was reported in academic literature as a novel chemotype with activity at low micromolar concentrations against multiple clinically important organisms, but without a fully elucidated molecular target or detailed clinical development path. Publicly available information focuses mainly on in vitro microbiology and preliminary structure–activity relationships, and there is no clear evidence of advanced clinical development or regulatory approval.